Search research articles
Contact Us
Filters
Showing results (81-90 of 117) with videos related to
Page
of 12
Sort By:
Breast Cancer Research and Treatment
|
March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
Elie Rassy, Thomas Filleron, Alessandro Viansone, et al.
Histopathology
|
April 11, 2012
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis
Felipe C Geyer, Magali Lacroix-Triki, Pierre-Emmanuel Colombo, et al.
British Journal of Cancer
|
August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Breast Cancer
|
January 12, 2022
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
Sherene Loi, Roberto Salgado, Sylvia Adams, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer
Mario Campone, Magali Lacroix-Triki, Lise Roca, et al.
The Lancet. Oncology
|
December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2019
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi, Damien Drubay, Sylvia Adams, et al.
Lancet (London, England)
|
August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
Ebiomedicine
|
May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
Sylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Clinical Pharmacology and Therapeutics
|
August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial
Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 117) with videos related to
Sort By:
Page
of 12
Breast Cancer Research and Treatment
|
March 29, 2023
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials
Elie Rassy, Thomas Filleron, Alessandro Viansone, et al.
Histopathology
|
April 11, 2012
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis
Felipe C Geyer, Magali Lacroix-Triki, Pierre-Emmanuel Colombo, et al.
British Journal of Cancer
|
August 1, 2024
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
Marie-Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, et al.
NPJ Breast Cancer
|
January 12, 2022
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
Sherene Loi, Roberto Salgado, Sylvia Adams, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2018
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer
Mario Campone, Magali Lacroix-Triki, Lise Roca, et al.
The Lancet. Oncology
|
December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2019
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi, Damien Drubay, Sylvia Adams, et al.
Lancet (London, England)
|
August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
Ebiomedicine
|
May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
Sylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Clinical Pharmacology and Therapeutics
|
August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial
Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
Page
of 12